← Back to headlines
Gilead Sciences Q2 Sales Boosted by HIV and Oncology Growth
Gilead Sciences reported a 10% jump in Q2 base sales, driven by strong growth in its HIV and oncology segments, despite a decline in Veklury sales.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
